Regeneron Pharmaceuticals Inc (REGN)vsRoyalty Pharma Plc (RPRX)
REGN
Regeneron Pharmaceuticals Inc
$927.89
+13.33%
HEALTHCARE · Cap: $95.99B
RPRX
Royalty Pharma Plc
$67.18
+1.90%
HEALTHCARE · Cap: $37.72B
Smart Verdict
WallStSmart Research — data-driven comparison
Regeneron Pharmaceuticals Inc generates 566% more annual revenue ($16.90B vs $2.54B). RPRX leads profitability with a 32.0% profit margin vs 28.5%. RPRX appears more attractively valued with a PEG of 1.51. REGN earns a higher WallStSmart Score of 78/100 (B+).
REGN
Strong Buy78
out of 100
Grade: B+
RPRX
Buy55
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+38.3%
Fair Value
$1504.34
Current Price
$927.89
$576.45 discount
Margin of Safety
-73.5%
Fair Value
$37.37
Current Price
$67.18
$29.81 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Strong operational efficiency at 40.5%
Revenue surging 36.3% year-over-year
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Large-cap with strong market position
Keeps 29 of every $100 in revenue as profit
Keeps 32 of every $100 in revenue as profit
16.5% revenue growth
Areas to Watch
Expensive relative to growth rate
Weak financial health signals
Expensive relative to growth rate
Premium valuation, high expectations priced in
Elevated debt levels
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : REGN
The strongest argument for REGN centers on Operating Margin, Revenue Growth, Debt/Equity. Profitability is solid with margins at 28.5% and operating margin at 40.5%. Revenue growth of 36.3% demonstrates continued momentum.
Bull Case : RPRX
The strongest argument for RPRX centers on Profit Margin, Revenue Growth. Profitability is solid with margins at 32.0% and operating margin at 19.8%. Revenue growth of 16.5% demonstrates continued momentum.
Bear Case : REGN
The primary concerns for REGN are PEG Ratio, Piotroski F-Score.
Bear Case : RPRX
The primary concerns for RPRX are PEG Ratio, P/E Ratio, Debt/Equity.
Key Dynamics to Monitor
RPRX carries more volatility with a beta of 0.41 — expect wider price swings.
REGN is growing revenue faster at 36.3% — sustainability is the question.
RPRX generates stronger free cash flow (686M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
REGN scores higher overall (78/100 vs 55/100), backed by strong 28.5% margins and 36.3% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Regeneron Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company then branched out into the study of both cytokine and tyrosine kinase receptors.
Royalty Pharma Plc
HEALTHCARE · BIOTECHNOLOGY · USA
Royalty Pharma plc is a buyer of biopharmaceutical royalties and funder of innovations in the biopharmaceutical industry in the United States. The company is headquartered in New York, New York.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?